英国采购需求：冷冻消融设备、精密冷疗设备、实体瘤治疗方案、冷冻消融技术供应商、医用冷冻治疗系统、肿瘤冷疗产品

In September 2025, the patient, a 50-year-old male diagnosed with metastatic gallbladder cancer, underwent initial treatment with five cycles of gemcitabine, cisplatin, and durvalumab, but experienced tumor progression afterwards. Subsequently, he received six cycles of FOLFOX, which also led to further progression. Currently, the focus is on symptom control, and the patient is actively exploring clinical trial opportunities to manage his condition more effectively. Given the history and current status, we're interested in the feasibility of alternative treatment options, particularly cryotherapy and oncolytic virotherapy. Could you provide insights into whether these therapies may be viable for this patient, along with any relevant data or considerations that might support their use in this context?